Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia

Phase 2

Terminated

• Conditions: Arrhythmias

• Registration Number: NCT00124891
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or myocardial infarction without ST elevation).

Detailed Description

Not available

Study Timeline

• Study Start: 2005-06-01
• Study First Submitted: 2005-07-13
• Study First Submitted QC: 2005-07-26
• Study First Posted: 2005-07-28
• Primary Completion: 2006-11-01
• Study Completion: 2006-11-01
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-28
• Last Update Posted: 2022-05-03

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
The total number of ventricular beats recorded by Holter monitoring during the 24 hr. on-therapy phase.

Secondary Outcome Measures

Name	Time	Method
The total number of NSVT beats, PVCs/couplets, NSVT episodes during the 24 hr. on-therapy phase and incidence of new-onset atrial fibrillation during the 24hr. on-therapy phase.